Literature DB >> 17304459

Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

Stuart Johnson1, Christopher Schriever, Minerva Galang, Ciarán P Kelly, Dale N Gerding.   

Abstract

Eight women who each experienced 4-8 episodes of Clostridium difficile-associated diarrhea were given a 2-week course of rifaximin therapy when they were asymptomatic, immediately after completing their last course of vancomycin therapy. Seven of the 8 patients experienced no further diarrhea recurrence. The patient who had a recurrence responded to a second course of rifaximin therapy, but rifaximin-resistant C. difficile was recovered after treatment. A controlled trial for treating recurrent Clostridium difficile-associated diarrhea appears to be warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304459     DOI: 10.1086/511870

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  82 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 2.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 3.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 4.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

5.  Rifaximin: recent advances in gastroenterology and hepatology.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

6.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

7.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

8.  Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  S M Finegold; D Molitoris; M-L Väisänen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  The effect of rifaximin on gut flora and Staphylococcus resistance.

Authors:  Mi-Sung Kim; Walter Morales; Andres Ardila Hani; Sharon Kim; Gene Kim; Stacy Weitsman; Christopher Chang; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

10.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Authors:  Scott R Curry; Jane W Marsh; Kathleen A Shutt; Carlene A Muto; Mary M O'Leary; Melissa I Saul; A William Pasculle; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.